Remington House, a once-notorious hijacked building in Johannesburg, has been transformed into fully let student housing, illustrating what is possible when intervention is followed through ...
A new national snapshot is shedding light on how Americans view President Donald Trump as major issues continue to dominate ...
Detailed price information for Mortgage Real Estate Ishares ETF (REM-A) from The Globe and Mail including charting and trades.
You’ll naturally earn this Read Earth Memory as you enter Block 03, when Diana discovers a half finished globe. So there’s nothing extra you need to do here! Just remember to gift it to Diana when you ...
William Bruneau's third experience using Montreal's light-rail network didn't go as planned. On Friday night, after attending an event in Montreal, he was heading back to Deux-Montagnes, north of ...
The third branch of Montreal's new light rail network is set to open on May 18. The Réseau express métropolitain (REM)'s Anse-à-l'Orme branch will extend the network by 14 kilometres, adding four new ...
A1 (Brossard), A4 (Deux-Montagnes) and A3 (Anse-à-l’Orme). REM users will have to remember those alphanumeric codes when the Anse-à-l’Orme branch begins accepting its first passengers on May 18. And ...
A new branch of Montreal’s REM light-rail system is set to open May 18, expanding the network in the city’s West Island region. The Anse-à-l’Orme line is the third to open and will have four stations ...
Nasdaq Inc. is among a group of investors backing a carbon-capture project in Stockholm, in what is the first sale of carbon-removal credits licensed by the European Union. The EU initiative aims to ...
(MENAFN- GlobeNewsWire - Nasdaq) Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader No Approved ...
WATERTOWN, Mass., March 19, 2026 (GLOBE NEWSWIRE)-- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader No Approved Treatment Options for Patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results